Cardinal's TERN-701 trial advanced in CML, showing enhanced potency compared to asciminib.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cardinal's TERN-701 trial advanced in CML, showing enhanced potency compared to asciminib.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cardinal
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireTerns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Phase 1 trial of TERN-701 in chronic myeloid leukemia (CML) enrolling well; efficacy and safety data